Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: EI 546; Elaspol; LY 544349; ONO 5046; ONO 5046 . Na; ONO 5406; ONO 5406 . Na

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Amino acids; Antiasthmatics; Antineoplastics; Antirheumatics; Sulfonamides
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lung injury
  • Discontinued Adult respiratory distress syndrome; Lung disorders; Lung transplant rejection; Non-small cell lung cancer; Pulmonary fibrosis; Respiratory insufficiency; Rheumatoid arthritis

Most Recent Events

  • 13 May 2010 Discontinued - Phase-II for Respiratory insufficiency in Japan (unspecified route)
  • 30 Oct 2009 Sivelestat is still in phase II trials for respiratory insufficiency in Japan
  • 20 Dec 2006 Launched for Acute lung injury in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top